Related Experiment Video
Updated: May 16, 2026
09:18
Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux
Published on: September 17, 2019
Dissecting bortezomib: development, application, adverse effects and future direction
Biyin Cao1, Jie Li, Xinliang Mao
1Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, The First Affiliated Hospital, Soochow University, Suzhou, China.
Current Pharmaceutical Design
|November 16, 2012
Summary
Bortezomib is a key proteasome inhibitor for multiple myeloma and lymphoma. This review covers its development, mechanisms, challenges like resistance, and future directions for improved cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Bortezomib is a first-in-class proteasome inhibitor.
- It is approved for multiple myeloma and mantle cell lymphoma.
- Its use is being explored for solid cancers and stem cell transplantation.
Purpose of the Study:
- To comprehensively review bortezomib's development and therapeutic mechanisms.
- To discuss challenges including adverse effects and drug resistance.
- To explore next-generation proteasome inhibitors and future research directions.
Main Methods:
- Literature review of bortezomib's clinical application and research.
- Analysis of mechanisms of action, resistance, and adverse events.
- Discussion of emerging therapeutic strategies and future prospects.
Main Results:
- Bortezomib demonstrates significant efficacy in hematological malignancies.
- Adverse effects and the development of drug resistance pose challenges.
- Ongoing research focuses on overcoming resistance and expanding bortezomib's therapeutic utility.
Conclusions:
- Bortezomib remains a vital therapeutic agent, but challenges require further investigation.
- Understanding resistance mechanisms is crucial for optimizing treatment.
- Future research aims to develop more effective proteasome inhibitors and combination therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...